| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.57(B) |
| Last
Volume: |
1,947,382 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,815,444 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
51 |
93 |
| End Date |
2024-03-30 |
2023-12-28 |
2023-06-29 |
2022-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fry Stephen F |
SVP, HR & Diversity |
• – – |
2019-02-04 |
4 |
A |
$120.17 |
$2,331,779 |
D/D |
19,404 |
124,509 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2019-02-04 |
4 |
A |
$120.17 |
$355,463 |
D/D |
2,958 |
20,817 |
|
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-02-04 |
4 |
A |
$120.17 |
$3,383,386 |
D/D |
28,155 |
126,299 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2019-02-04 |
4 |
A |
$120.17 |
$890,580 |
D/D |
7,411 |
26,820 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$178,711 |
I/I |
(1,491) |
52,684 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,221 |
54,175 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$478,841 |
D/D |
(3,995) |
105,105 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,889 |
109,100 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$178,831 |
D/D |
(1,492) |
19,409 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
20,901 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$656,353 |
D/D |
(5,476) |
131,280 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,222 |
136,756 |
|
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$527,863 |
D/D |
(4,404) |
98,144 |
|
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,778 |
102,548 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-02-01 |
4 |
D |
$119.86 |
$523,069 |
D/D |
(4,364) |
46,582 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,722 |
50,946 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2019-02-01 |
4 |
D |
$119.86 |
$657,432 |
D/D |
(5,485) |
126,223 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,222 |
131,708 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-01-31 |
4 |
AS |
$120.00 |
$480,000 |
D/D |
(4,000) |
41,224 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-01-22 |
4 |
A |
$117.09 |
$9,953 |
D/D |
85 |
211 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-01-22 |
4 |
A |
$117.09 |
$10,889 |
D/D |
93 |
43,373 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-01-22 |
4 |
A |
$117.09 |
$1,991 |
D/D |
17 |
54,847 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2019-01-22 |
4 |
A |
$117.09 |
$6,791 |
D/D |
58 |
56,200 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-01-22 |
4 |
A |
$117.09 |
$10,655 |
D/D |
91 |
8,207 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-01-17 |
4 |
S |
$118.11 |
$16,161,281 |
D/D |
(136,577) |
117,825,304 |
|
- |
|
1436 Records found
|
|
Page 31 of 58 |
|
|
7.78 (0.86%) 
